Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q1 FY22 results · Apr–Jun 2021
Panacea Biotec reported revenue from operations of ₹132.45 crore (down 0.2% from Q1 FY21) and net loss of ₹57.35 crore for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 132.45 | 132.76 | −0.2% | 168.27 | −21.3% |
| Other income | 3.23 | 1.19 | +171.4% | 4.90 | −34.1% |
| Total income | 135.68 | 133.95 | +1.3% | 173.17 | −21.6% |
| Profit before tax | (57.27) | (32.83) | Loss widened | (52.65) | Loss widened |
| Net profit for the period | (57.35) | (34.13) | Loss widened | (54.14) | Loss widened |
| EPS, basic (₹) | (9.36) | (5.58) | Loss widened | (8.84) | Loss widened |
| Net margin (%) | -43.3 | -25.7 | -32.2 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 36.26 | 76.48 | −52.6% | 79.86 | −54.6% |
| Other income | 4.15 | 2.87 | +44.6% | 7.75 | −46.5% |
| Total income | 40.41 | 79.35 | −49.1% | 87.61 | −53.9% |
| Profit before tax | (23.47) | (8.10) | Loss widened | (16.79) | Loss widened |
| Net profit for the period | (23.47) | (8.84) | Loss widened | (18.31) | Loss widened |
| EPS, basic (₹) | (3.83) | (1.45) | Loss widened | (2.99) | Loss widened |
| Net margin (%) | -64.7 | -11.6 | -22.9 |
Consolidated
- Filed with BSE
- 24 Jul 2021, 16:39 IST
- Board meeting
- 23 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jul 2021, 16:39 IST
- Board meeting
- 23 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE